La cadena de opciones muestra datos clave de las opciones de acciones de Instil Bio a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Instil Bio..

Instil Bio (NASDAQ:TIL) Bolsa, Cadena de Opciones

INSTIL BIO INC

Instil Bio

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Instil Bio Inc

Interface Inc

FlexShares Mornigstar US Market Factors Tilt Index Fund ETF

Listed Funds Trust Teucrium Agricultural Strategy No K-1 ETF

Till Capital Corp Shs Restricted Voting

Earnings

Press Releases

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

News

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

Management

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Health Care

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

ALNY

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Alpha Cognition

Agenus

Anika Therapeutics

Anixa Biosciences

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Atossa Therapeutics

Biomea Fusion

Climb Bio

Cardiff Oncology

Citius Oncology

Entera Bio

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Molecular Partners AG - American Depositary Shares

Molecular Partners

Oncolytics Biotech

Ovid Therapeutics

AVITA Medical

Spero Therapeutics

TScan Therapeutics

Tevogen Bio Holdings

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Jefferies

Baird

Truist Securities

Comments

Instil Bio

Instil Bio (TIL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL